Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 1,121–1,130 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 1121
- Medicine slug
- olanzapine
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 104
- Source count
- 103
- Agreement rate
- 1
- Recorded readings
6 hours
- Numeric value
- 6
- Unit
- hours
- Source records
- 103
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 103 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4d768cfe-3b20-4127-95b9-b4151b28afcc (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6a279fe1-ed99-4a62-b2c7-831961470fa9 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy - Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2cb1bebe-0ced-46d8-bf21-c28a9acc4a15 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e40d54bf-7334-4418-8a87-ff85941adec1 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7772a4c2-1fb1-412b-9e3b-ef3d693517a2 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c47f90fc-49fe-4f60-9da8-1365a1650dd9 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c745e2e-89d3-44d4-906e-704705c33310 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52bdaaaf-ab54-99d1-e063-6394a90a521f (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1705bab2-a2f8-4534-b1fc-eb309cd2696b (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2a7300d3-95e3-427e-bf37-55fa654cc90a (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b6f0b2e2-3cbd-4564-8b3e-f811589af275 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5bded04a-d848-4ac6-b7c3-ff9b9fef3d29 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:87b7fb23-c9b7-433f-bd17-cd3e91714c27 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dbe23f33-9e7d-49a7-8528-fa290661a96f (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:032e589c-47b1-4eb1-9466-8160297b81e9 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b418946a-1ab4-4d89-a012-d94fc361a3c4 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:42d9ad47-52cc-ad11-e063-6394a90aedca (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed93d6b9-912a-444a-a695-439d0bfb877a (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ce66d545-015b-41d5-80c3-964d78e36bfd (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:88edb3fc-fcb6-4483-859d-f830b077aca2 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:63bcfe98-d1fc-4cd7-9212-f59ee4dcc6d1 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:495efc49-7cdb-4b9e-e063-6394a90a547e (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4d34f8f3-edc8-0a68-e063-6394a90a9c1f (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:028aa88e-fa50-7aa8-cc0b-97c0c9a0357c (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:024e8e9b-a4fc-4882-b080-c070467166a6 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:22528ae1-e36f-48e1-e063-6294a90a3dd2 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine binds with low affinity to GABAA, BZD, and β-adrenergic receptors (Ki>10 μM). 12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:54adae9e-6781-6a77-e063-6394a90ab5c8 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:002dd00f-7946-ea4f-e063-6294a90a5916 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c1387008-6dc4-4f1e-ae29-fa7a0f0be684 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0ecbf540-572e-4ca4-b694-18ca1cd1c194 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:76a6ff21-7157-4213-8073-35837a3ac07e (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:709d79a1-2742-4629-af43-161be166833a (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4d1b83db-54db-d51f-e063-6394a90a4a69 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:96165590-b287-0ed9-3723-752af59aedad (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e6ffcc56-63f9-4b12-a07a-c6177ffef5e8 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine binds with low affinity to GABA A, BZD, and β-adrenergic receptors (K i >10 μM). 12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3347d1c8-04c9-5ce1-8cda-b38e0412b709 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e9ac2bd3-dbff-4b1a-952f-da3909c6e4ee (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:979c3212-36e8-4287-aace-bef0875188d7 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:549dc142-adcd-99ed-e063-6294a90a37fa (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c47ee16f-5a86-49f2-8d85-5f49a6c8d91e (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d5a9f78e-56f4-4249-800c-5f52a99fa84b (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cfc0f187-d3ff-4bbb-9129-0e94c6eda0ee (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:df43938a-3469-40eb-8166-f0a2fd29d6d8 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3aad0f7b-8d0c-a9bf-e063-6394a90a6ae8 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy - Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51b508ff-dc55-ff36-e063-6294a90a900f (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f0943b4e-6bdc-48c1-8ecd-39cf732e16f5 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e830f488-c689-40f6-9351-f9c7454ff1ea (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a4c525da-c2f6-b804-af49-601295922254 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9eb6b0d1-b301-4847-88f5-f8613d550ecc (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5ba67321-6988-46ea-97a0-549954e2c405 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d349d5b7-5658-46d6-9bba-e6f6361cebb9 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6fd7ceb-1457-4c3e-9d30-4f658f39d37d (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9a57a63e-f856-aafa-037a-c08f2fea6496 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fcec190f-b865-c5d3-e053-6394a90a7e45 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine binds with low affinity to GABAA, BZD, and β-adrenergic receptors (Ki>10 μM). 12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:325d5d69-5133-79ea-e063-6294a90afdd0 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9847a0e4-24fc-f4e8-e053-2995a90a961e (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9d9f25d5-4513-434a-a37a-392a0c978f2e (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy - Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8e095987-bdea-42f2-9550-c7155cf07d30 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dd0b2525-4e2f-44fc-9302-0ae4ebb1e135 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1e9666ef-4271-4834-8496-ccb3125d83db (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:38a89689-efc2-4931-8f65-868dc0248d6a (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:636665be-9d7e-443a-8134-e8cc47e6ba24 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:61424fa3-b09a-4267-a208-a7c7c3f69fe5 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b6ec5610-b4a6-4646-954a-0fe8b1d3e143 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:09e48e71-4dd2-4538-91d7-5b284f6647d8 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:58f175a8-5549-4f9e-baf4-8dc340c2cfd5 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1866a03c-eac9-44a1-8f33-7dc6e8a8c06a (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37c88965-c51d-946d-e063-6394a90a012c (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e8626e68-088d-47ff-bf06-489a778815aa (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c0d705bf-b719-4c7b-b83d-c17d41cbbfad (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy – Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2e709eaf-4116-4ee3-8dff-ace36181d115 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine binds with low affinity to GABA A, BZD, and β-adrenergic receptors (K i >10 μM). 12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a1dfb4e7-4143-4422-b7a7-292e4fd75044 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52b99337-afa8-a6f9-e063-6294a90a2038 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4e90e30c-78a1-486f-a13c-f1ff798216be (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d474d5a9-d338-511d-5823-567c0a1bbf4d (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3d69af75-7615-4ec2-b7ef-467b2558c5c8 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f4e41c2c-d32d-40c2-8afb-b6df998ba6b0 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10043041-a632-4e57-bc08-37216dea8546 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3ed78a7d-4014-d280-e063-6294a90a8ee9 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:518a9400-edb8-6403-e063-6294a90a065d (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51b64b6d-4676-a637-e063-6394a90a450c (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:55669a10-93f3-cfd6-e063-6294a90aa0e6 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ad350abc-a1fc-4be4-b2be-c629121552a0 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:68de2a51-69b2-4d99-be79-36a95a4bc475 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aff02cff-d079-bc82-6182-a24c4c6e09a6 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1f4a2eaf-3a12-4ebe-b97f-0a7bfbc32572 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8586e828-34e7-4eb4-a933-6c688927478f (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dcf8fcbf-636c-41ad-8084-c65ac2f117cc (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dc56c264-d10e-4059-b0d5-2feff16b345d (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8f485576-a4c4-45d4-816f-2e59fce9f517 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine binds with low affinity to GABA A , BZD, and β-adrenergic receptors (K i >10 μM). 12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:55668be2-62ac-3252-e063-6394a90a40f7 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ea3259d5-36ee-4ac9-b849-9625626e2187 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3c9963b1-c498-48a0-a3a1-1eaa6a1028fc (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d3857220-d9ff-4820-bf53-f2384b59a1a6 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6077f5c4-01d7-4c1d-97a0-cb859f98ce68 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:75616c31-8fed-4014-a9f2-4a028eccd586 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy – Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:12ce860a-6f22-4db6-8acf-786b40f5a5a5 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:40187874-447a-de20-e063-6394a90aafe7 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c44a96cc-817d-4eb5-a13a-00977f76e666 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:53e6b4e9-de26-16c3-e063-6294a90a7764 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8e5ef52d-315b-4055-9e52-403e6f896f24 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b513823d-927c-4111-8766-e6c37f84b221 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2ae07ad4-4e58-4740-9f02-035ec061fefc (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Oral Administration, Monotherapy — Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
Projected row 1122
- Medicine slug
- olanzapine
- Compared field
- volumeOfDistribution
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 104
- Source count
- 104
- Agreement rate
- 0.740385
- Recorded readings
1000 L
- Numeric value
- 1,000
- Unit
- L
- Source records
- 77
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 77 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4d768cfe-3b20-4127-95b9-b4151b28afcc (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6a279fe1-ed99-4a62-b2c7-831961470fa9 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e40d54bf-7334-4418-8a87-ff85941adec1 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c47f90fc-49fe-4f60-9da8-1365a1650dd9 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c745e2e-89d3-44d4-906e-704705c33310 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52bdaaaf-ab54-99d1-e063-6394a90a521f (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1705bab2-a2f8-4534-b1fc-eb309cd2696b (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2a7300d3-95e3-427e-bf37-55fa654cc90a (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b6f0b2e2-3cbd-4564-8b3e-f811589af275 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5bded04a-d848-4ac6-b7c3-ff9b9fef3d29 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:87b7fb23-c9b7-433f-bd17-cd3e91714c27 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:11544cba-64a9-49cb-8d74-da228053b252 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b418946a-1ab4-4d89-a012-d94fc361a3c4 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ce66d545-015b-41d5-80c3-964d78e36bfd (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:88edb3fc-fcb6-4483-859d-f830b077aca2 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:63bcfe98-d1fc-4cd7-9212-f59ee4dcc6d1 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4d34f8f3-edc8-0a68-e063-6394a90a9c1f (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:028aa88e-fa50-7aa8-cc0b-97c0c9a0357c (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:22528ae1-e36f-48e1-e063-6294a90a3dd2 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:54adae9e-6781-6a77-e063-6394a90ab5c8 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:002dd00f-7946-ea4f-e063-6294a90a5916 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c1387008-6dc4-4f1e-ae29-fa7a0f0be684 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0ecbf540-572e-4ca4-b694-18ca1cd1c194 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:76a6ff21-7157-4213-8073-35837a3ac07e (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:709d79a1-2742-4629-af43-161be166833a (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4d1b83db-54db-d51f-e063-6394a90a4a69 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e6ffcc56-63f9-4b12-a07a-c6177ffef5e8 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Plasma concentrations, half-life, and clearance of olanzapine may vary between individuals on the basis of smoking status, gender, and age.Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e9ac2bd3-dbff-4b1a-952f-da3909c6e4ee (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:979c3212-36e8-4287-aace-bef0875188d7 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:549dc142-adcd-99ed-e063-6294a90a37fa (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c47ee16f-5a86-49f2-8d85-5f49a6c8d91e (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cfc0f187-d3ff-4bbb-9129-0e94c6eda0ee (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:df43938a-3469-40eb-8166-f0a2fd29d6d8 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3aad0f7b-8d0c-a9bf-e063-6394a90a6ae8 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51b508ff-dc55-ff36-e063-6294a90a900f (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a4c525da-c2f6-b804-af49-601295922254 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9eb6b0d1-b301-4847-88f5-f8613d550ecc (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d349d5b7-5658-46d6-9bba-e6f6361cebb9 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6fd7ceb-1457-4c3e-9d30-4f658f39d37d (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9a57a63e-f856-aafa-037a-c08f2fea6496 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fcec190f-b865-c5d3-e053-6394a90a7e45 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9d9f25d5-4513-434a-a37a-392a0c978f2e (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8e095987-bdea-42f2-9550-c7155cf07d30 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dd0b2525-4e2f-44fc-9302-0ae4ebb1e135 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1e9666ef-4271-4834-8496-ccb3125d83db (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:38a89689-efc2-4931-8f65-868dc0248d6a (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:636665be-9d7e-443a-8134-e8cc47e6ba24 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:61424fa3-b09a-4267-a208-a7c7c3f69fe5 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:09e48e71-4dd2-4538-91d7-5b284f6647d8 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c0d705bf-b719-4c7b-b83d-c17d41cbbfad (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2e709eaf-4116-4ee3-8dff-ace36181d115 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52b99337-afa8-a6f9-e063-6294a90a2038 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4e90e30c-78a1-486f-a13c-f1ff798216be (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d474d5a9-d338-511d-5823-567c0a1bbf4d (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3d69af75-7615-4ec2-b7ef-467b2558c5c8 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f4e41c2c-d32d-40c2-8afb-b6df998ba6b0 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10043041-a632-4e57-bc08-37216dea8546 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:518a9400-edb8-6403-e063-6294a90a065d (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51b64b6d-4676-a637-e063-6394a90a450c (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:55669a10-93f3-cfd6-e063-6294a90aa0e6 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ad350abc-a1fc-4be4-b2be-c629121552a0 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:68de2a51-69b2-4d99-be79-36a95a4bc475 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aff02cff-d079-bc82-6182-a24c4c6e09a6 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1f4a2eaf-3a12-4ebe-b97f-0a7bfbc32572 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8586e828-34e7-4eb4-a933-6c688927478f (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dcf8fcbf-636c-41ad-8084-c65ac2f117cc (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dc56c264-d10e-4059-b0d5-2feff16b345d (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8f485576-a4c4-45d4-816f-2e59fce9f517 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:55668be2-62ac-3252-e063-6394a90a40f7 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ea3259d5-36ee-4ac9-b849-9625626e2187 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3c9963b1-c498-48a0-a3a1-1eaa6a1028fc (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:75616c31-8fed-4014-a9f2-4a028eccd586 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:12ce860a-6f22-4db6-8acf-786b40f5a5a5 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c44a96cc-817d-4eb5-a13a-00977f76e666 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:53e6b4e9-de26-16c3-e063-6294a90a7764 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8e5ef52d-315b-4055-9e52-403e6f896f24 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b513823d-927c-4111-8766-e6c37f84b221 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000 L.
1,000 L
- Numeric value
- 1,000
- Unit
- L
- Source records
- 27
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 27 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2cb1bebe-0ced-46d8-bf21-c28a9acc4a15 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1,000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7772a4c2-1fb1-412b-9e3b-ef3d693517a2 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1,000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dbe23f33-9e7d-49a7-8528-fa290661a96f (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1,000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:032e589c-47b1-4eb1-9466-8160297b81e9 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1,000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:42d9ad47-52cc-ad11-e063-6394a90aedca (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1,000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed93d6b9-912a-444a-a695-439d0bfb877a (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1,000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:495efc49-7cdb-4b9e-e063-6394a90a547e (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1,000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:024e8e9b-a4fc-4882-b080-c070467166a6 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1,000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:96165590-b287-0ed9-3723-752af59aedad (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1,000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3347d1c8-04c9-5ce1-8cda-b38e0412b709 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1,000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d5a9f78e-56f4-4249-800c-5f52a99fa84b (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1,000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f0943b4e-6bdc-48c1-8ecd-39cf732e16f5 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1,000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e830f488-c689-40f6-9351-f9c7454ff1ea (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1,000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5ba67321-6988-46ea-97a0-549954e2c405 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1,000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:325d5d69-5133-79ea-e063-6294a90afdd0 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1,000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9847a0e4-24fc-f4e8-e053-2995a90a961e (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1,000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b6ec5610-b4a6-4646-954a-0fe8b1d3e143 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1,000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:58f175a8-5549-4f9e-baf4-8dc340c2cfd5 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1,000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1866a03c-eac9-44a1-8f33-7dc6e8a8c06a (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1,000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:37c88965-c51d-946d-e063-6394a90a012c (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1,000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e8626e68-088d-47ff-bf06-489a778815aa (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1,000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a1dfb4e7-4143-4422-b7a7-292e4fd75044 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1,000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3ed78a7d-4014-d280-e063-6294a90a8ee9 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1,000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d3857220-d9ff-4820-bf53-f2384b59a1a6 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1,000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6077f5c4-01d7-4c1d-97a0-cb859f98ce68 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1,000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:40187874-447a-de20-e063-6394a90aafe7 (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1,000 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2ae07ad4-4e58-4740-9f02-035ec061fefc (opens source in a new tab)
Olanzapine label
Version not recorded · Effective date not recorded
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1,000 L.
Projected row 1123
- Medicine slug
- olmesartan-medoxomil
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 73
- Source count
- 73
- Agreement rate
- 1
- Recorded readings
26%
- Numeric value
- 26
- Unit
- %
- Source records
- 73
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 73 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b57e47a5-43e0-d1c5-e053-2a95a90a2b07 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a4ceea38-8fff-4317-be04-8dc22222ec70 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1f430fc9-bd4c-4328-a4a2-501ec991029b (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:142b735a-e1cd-46e1-a523-3ef061001bf9 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e5dbca00-4e1b-4479-b829-021b11bc021e (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8e0adf3d-7569-4909-bab1-5fed9578ad77 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4a2aad53-fcba-2a61-e063-6394a90a6016 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:79e2620d-6554-4e03-8087-59ec2e4dd75b (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2bb63404-7d54-4482-8377-6ff02052892a (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ac08ea7d-f529-42ca-850a-a0ecce7dc830 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4238a064-1bfd-4ce3-b9d9-12c96eee8af0 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b55b6172-d986-4fd9-ba85-a8393c908949 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:879630ff-662a-40bd-b74f-a864661dea95 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c5416a9f-1dcc-4851-bbc0-6664d22fc8fa (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:640936ee-55a6-47ae-a1ad-cffae316b925 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:85a24657-583b-4776-98c9-b30285cb3058 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7835d2b0-8e5d-4d3f-a95f-9252fb65025b (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe6e39da-fb6e-46da-9c03-c765020a7c87 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6b8585a2-22e0-4a4f-a1c3-24bcdec01834 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:05a807bf-5175-43a2-a676-215bba2645a8 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:949e6bad-fcb2-42f2-b9c8-e5620ef5ccd5 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cf4f62f9-5a00-4313-b703-ec0ac6380b5e (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5f410909-a68a-4ada-963a-32018d37572f (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eff499eb-a0e4-4240-870c-83bb53434cc2 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5972c6fd-08e3-4189-a894-1ba220b57e80 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4bf142a3-ad7f-4ed5-98c2-54d8509b7dbc (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:53b8d406-a4f3-46ee-9aec-d70f7d806876 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c620361a-dc2d-28a1-e053-2995a90abd14 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3c001b8d-f6c1-4316-b8c0-590b2fa7f2e5 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a337a621-bf57-4aa4-8224-4356fa2cdbc4 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33429d86-878e-4e1e-a940-70a8a56a15ea (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:26065167-37c9-4e95-aa2c-3005b6805a52 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eeb16efc-4413-4464-9eb8-effa1e5684aa (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6e602f81-1cc3-4ae1-8bdf-85572e35cf73 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5b6f8a18-8f8a-4521-81c3-3a39c73c6646 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:812d2d57-14d6-48a9-9687-85c2d125197e (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c35408d2-a4b5-43de-8dab-f74a60fa9853 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:409e06ad-2ea9-4b47-829e-57139e22eac9 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:25431c8c-9f6e-42e7-ab84-4b062755bfe3 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8a021ffc-8b11-4ddf-81c4-87515971fdee (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f15664a4-6b5f-4e88-ad56-c827ed90a40c (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1be698df-30a0-4117-8c24-7253af94c8ad (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8466711a-3a02-4675-96db-c7cffdb89778 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d5658d8a-f8e9-454d-89a9-34884e753001 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92969ed0-8dcd-4c6d-b0c4-e8469c2f65a9 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9d9f1c08-4f65-484c-943e-7e664281910f (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16754802-d5a4-0350-e063-6394a90aa967 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ba299e7-0651-c23b-e063-6294a90a0245 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:04f0107b-4194-4412-9ebb-3219da5a9ac9 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:98f930d5-f7c2-4870-92b4-0ad37ce45797 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eff8b514-bb7f-427e-a267-7dee25fff611 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe80fd21-fa8d-474e-ac0a-23f0e1eb7f3b (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8c94d403-809b-43b9-834f-3ecd330d2dd9 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e64c3b3b-d5e7-6d46-e053-2a95a90a1b64 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cae6cb47-0a2c-4c69-894b-89d389cab49f (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:67aa498d-edf6-45b8-a3fd-019c3fb76960 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:24e308cc-7cec-4054-9627-66f743ed71b0 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b02ff20e-3f0e-43f4-a7b5-6ce56295d023 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e210f962-9b91-46c6-af8f-9f9a9ae84245 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7afa79de-d42e-4429-874d-449d47a59fbe (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:afcfc1eb-29b1-46e8-a013-5cbb1737a232 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c49a7f23-2af0-4607-9f21-114970f8630d (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7f78d14a-acf2-4f82-9d20-dfcbd5e9ffb3 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dc3f1fd4-5578-4c5d-be7b-12e3f8f3e7df (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:38f7f201-3a3a-4922-bde7-d34187b4c81d (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8acdc142-aa38-4fcb-bd15-fbba9635a4c6 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f4d89ab-58c8-27ea-e063-6394a90a8723 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16752f60-655a-f727-e063-6394a90a96b6 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a49d951-dd1b-413b-99e5-d3119267c46c (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e43e5643-b258-469d-812a-887f913cfe71 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:865c2765-5072-d029-e053-2a91aa0a098e (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57dc737b-01e2-4b22-991f-d4710950dcf3 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1df1ff60-6be5-4018-a28c-0d23e5867eba (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
The absolute bioavailability of olmesartan is approximately 26%.
Projected row 1124
- Medicine slug
- olmesartan-medoxomil
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 73
- Source count
- 73
- Agreement rate
- 1
- Recorded readings
13 hours
- Numeric value
- 13
- Unit
- hours
- Source records
- 73
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 73 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b57e47a5-43e0-d1c5-e053-2a95a90a2b07 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a4ceea38-8fff-4317-be04-8dc22222ec70 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1f430fc9-bd4c-4328-a4a2-501ec991029b (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:142b735a-e1cd-46e1-a523-3ef061001bf9 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e5dbca00-4e1b-4479-b829-021b11bc021e (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8e0adf3d-7569-4909-bab1-5fed9578ad77 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4a2aad53-fcba-2a61-e063-6394a90a6016 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:79e2620d-6554-4e03-8087-59ec2e4dd75b (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2bb63404-7d54-4482-8377-6ff02052892a (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ac08ea7d-f529-42ca-850a-a0ecce7dc830 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4238a064-1bfd-4ce3-b9d9-12c96eee8af0 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b55b6172-d986-4fd9-ba85-a8393c908949 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:879630ff-662a-40bd-b74f-a864661dea95 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c5416a9f-1dcc-4851-bbc0-6664d22fc8fa (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:640936ee-55a6-47ae-a1ad-cffae316b925 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:85a24657-583b-4776-98c9-b30285cb3058 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7835d2b0-8e5d-4d3f-a95f-9252fb65025b (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe6e39da-fb6e-46da-9c03-c765020a7c87 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6b8585a2-22e0-4a4f-a1c3-24bcdec01834 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:05a807bf-5175-43a2-a676-215bba2645a8 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:949e6bad-fcb2-42f2-b9c8-e5620ef5ccd5 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cf4f62f9-5a00-4313-b703-ec0ac6380b5e (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5f410909-a68a-4ada-963a-32018d37572f (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eff499eb-a0e4-4240-870c-83bb53434cc2 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5972c6fd-08e3-4189-a894-1ba220b57e80 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4bf142a3-ad7f-4ed5-98c2-54d8509b7dbc (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:53b8d406-a4f3-46ee-9aec-d70f7d806876 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c620361a-dc2d-28a1-e053-2995a90abd14 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3c001b8d-f6c1-4316-b8c0-590b2fa7f2e5 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a337a621-bf57-4aa4-8224-4356fa2cdbc4 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33429d86-878e-4e1e-a940-70a8a56a15ea (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:26065167-37c9-4e95-aa2c-3005b6805a52 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eeb16efc-4413-4464-9eb8-effa1e5684aa (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6e602f81-1cc3-4ae1-8bdf-85572e35cf73 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5b6f8a18-8f8a-4521-81c3-3a39c73c6646 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:812d2d57-14d6-48a9-9687-85c2d125197e (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c35408d2-a4b5-43de-8dab-f74a60fa9853 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:409e06ad-2ea9-4b47-829e-57139e22eac9 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:25431c8c-9f6e-42e7-ab84-4b062755bfe3 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8a021ffc-8b11-4ddf-81c4-87515971fdee (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f15664a4-6b5f-4e88-ad56-c827ed90a40c (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1be698df-30a0-4117-8c24-7253af94c8ad (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8466711a-3a02-4675-96db-c7cffdb89778 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d5658d8a-f8e9-454d-89a9-34884e753001 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92969ed0-8dcd-4c6d-b0c4-e8469c2f65a9 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9d9f1c08-4f65-484c-943e-7e664281910f (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16754802-d5a4-0350-e063-6394a90aa967 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ba299e7-0651-c23b-e063-6294a90a0245 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:04f0107b-4194-4412-9ebb-3219da5a9ac9 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:98f930d5-f7c2-4870-92b4-0ad37ce45797 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eff8b514-bb7f-427e-a267-7dee25fff611 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe80fd21-fa8d-474e-ac0a-23f0e1eb7f3b (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8c94d403-809b-43b9-834f-3ecd330d2dd9 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e64c3b3b-d5e7-6d46-e053-2a95a90a1b64 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cae6cb47-0a2c-4c69-894b-89d389cab49f (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:67aa498d-edf6-45b8-a3fd-019c3fb76960 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:24e308cc-7cec-4054-9627-66f743ed71b0 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b02ff20e-3f0e-43f4-a7b5-6ce56295d023 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e210f962-9b91-46c6-af8f-9f9a9ae84245 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7afa79de-d42e-4429-874d-449d47a59fbe (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:afcfc1eb-29b1-46e8-a013-5cbb1737a232 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c49a7f23-2af0-4607-9f21-114970f8630d (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7f78d14a-acf2-4f82-9d20-dfcbd5e9ffb3 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dc3f1fd4-5578-4c5d-be7b-12e3f8f3e7df (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:38f7f201-3a3a-4922-bde7-d34187b4c81d (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8acdc142-aa38-4fcb-bd15-fbba9635a4c6 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f4d89ab-58c8-27ea-e063-6394a90a8723 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16752f60-655a-f727-e063-6394a90a96b6 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a49d951-dd1b-413b-99e5-d3119267c46c (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e43e5643-b258-469d-812a-887f913cfe71 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:865c2765-5072-d029-e053-2a91aa0a098e (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57dc737b-01e2-4b22-991f-d4710950dcf3 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1df1ff60-6be5-4018-a28c-0d23e5867eba (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan appears to be eliminated in a biphasic manner with a terminal elimination half-life of approximately 13 hours.
Projected row 1125
- Medicine slug
- olmesartan-medoxomil
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 73
- Source count
- 73
- Agreement rate
- 1
- Recorded readings
99%
- Numeric value
- 99
- Unit
- %
- Source records
- 73
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 73 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b57e47a5-43e0-d1c5-e053-2a95a90a2b07 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a4ceea38-8fff-4317-be04-8dc22222ec70 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1f430fc9-bd4c-4328-a4a2-501ec991029b (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:142b735a-e1cd-46e1-a523-3ef061001bf9 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e5dbca00-4e1b-4479-b829-021b11bc021e (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8e0adf3d-7569-4909-bab1-5fed9578ad77 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4a2aad53-fcba-2a61-e063-6394a90a6016 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:79e2620d-6554-4e03-8087-59ec2e4dd75b (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2bb63404-7d54-4482-8377-6ff02052892a (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ac08ea7d-f529-42ca-850a-a0ecce7dc830 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4238a064-1bfd-4ce3-b9d9-12c96eee8af0 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b55b6172-d986-4fd9-ba85-a8393c908949 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:879630ff-662a-40bd-b74f-a864661dea95 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c5416a9f-1dcc-4851-bbc0-6664d22fc8fa (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:640936ee-55a6-47ae-a1ad-cffae316b925 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:85a24657-583b-4776-98c9-b30285cb3058 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7835d2b0-8e5d-4d3f-a95f-9252fb65025b (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe6e39da-fb6e-46da-9c03-c765020a7c87 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6b8585a2-22e0-4a4f-a1c3-24bcdec01834 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:05a807bf-5175-43a2-a676-215bba2645a8 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:949e6bad-fcb2-42f2-b9c8-e5620ef5ccd5 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cf4f62f9-5a00-4313-b703-ec0ac6380b5e (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5f410909-a68a-4ada-963a-32018d37572f (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eff499eb-a0e4-4240-870c-83bb53434cc2 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5972c6fd-08e3-4189-a894-1ba220b57e80 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4bf142a3-ad7f-4ed5-98c2-54d8509b7dbc (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:53b8d406-a4f3-46ee-9aec-d70f7d806876 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c620361a-dc2d-28a1-e053-2995a90abd14 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3c001b8d-f6c1-4316-b8c0-590b2fa7f2e5 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a337a621-bf57-4aa4-8224-4356fa2cdbc4 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33429d86-878e-4e1e-a940-70a8a56a15ea (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:26065167-37c9-4e95-aa2c-3005b6805a52 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eeb16efc-4413-4464-9eb8-effa1e5684aa (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6e602f81-1cc3-4ae1-8bdf-85572e35cf73 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5b6f8a18-8f8a-4521-81c3-3a39c73c6646 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:812d2d57-14d6-48a9-9687-85c2d125197e (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c35408d2-a4b5-43de-8dab-f74a60fa9853 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:409e06ad-2ea9-4b47-829e-57139e22eac9 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:25431c8c-9f6e-42e7-ab84-4b062755bfe3 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8a021ffc-8b11-4ddf-81c4-87515971fdee (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f15664a4-6b5f-4e88-ad56-c827ed90a40c (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1be698df-30a0-4117-8c24-7253af94c8ad (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8466711a-3a02-4675-96db-c7cffdb89778 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d5658d8a-f8e9-454d-89a9-34884e753001 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92969ed0-8dcd-4c6d-b0c4-e8469c2f65a9 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9d9f1c08-4f65-484c-943e-7e664281910f (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16754802-d5a4-0350-e063-6394a90aa967 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ba299e7-0651-c23b-e063-6294a90a0245 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:04f0107b-4194-4412-9ebb-3219da5a9ac9 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:98f930d5-f7c2-4870-92b4-0ad37ce45797 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eff8b514-bb7f-427e-a267-7dee25fff611 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe80fd21-fa8d-474e-ac0a-23f0e1eb7f3b (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8c94d403-809b-43b9-834f-3ecd330d2dd9 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e64c3b3b-d5e7-6d46-e053-2a95a90a1b64 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cae6cb47-0a2c-4c69-894b-89d389cab49f (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:67aa498d-edf6-45b8-a3fd-019c3fb76960 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:24e308cc-7cec-4054-9627-66f743ed71b0 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b02ff20e-3f0e-43f4-a7b5-6ce56295d023 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e210f962-9b91-46c6-af8f-9f9a9ae84245 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7afa79de-d42e-4429-874d-449d47a59fbe (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:afcfc1eb-29b1-46e8-a013-5cbb1737a232 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c49a7f23-2af0-4607-9f21-114970f8630d (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7f78d14a-acf2-4f82-9d20-dfcbd5e9ffb3 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dc3f1fd4-5578-4c5d-be7b-12e3f8f3e7df (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:38f7f201-3a3a-4922-bde7-d34187b4c81d (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8acdc142-aa38-4fcb-bd15-fbba9635a4c6 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f4d89ab-58c8-27ea-e063-6394a90a8723 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16752f60-655a-f727-e063-6394a90a96b6 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a49d951-dd1b-413b-99e5-d3119267c46c (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e43e5643-b258-469d-812a-887f913cfe71 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:865c2765-5072-d029-e053-2a91aa0a098e (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57dc737b-01e2-4b22-991f-d4710950dcf3 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1df1ff60-6be5-4018-a28c-0d23e5867eba (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Olmesartan is highly bound to plasma proteins (99%) and does not penetrate red blood cells.
Projected row 1126
- Medicine slug
- olmesartan-medoxomil
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 73
- Source count
- 73
- Agreement rate
- 1
- Recorded readings
1 to 2 hours
- Numeric value
- 1
- Unit
- hours
- Source records
- 73
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 73 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b57e47a5-43e0-d1c5-e053-2a95a90a2b07 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a4ceea38-8fff-4317-be04-8dc22222ec70 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1f430fc9-bd4c-4328-a4a2-501ec991029b (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:142b735a-e1cd-46e1-a523-3ef061001bf9 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (Cmax) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e5dbca00-4e1b-4479-b829-021b11bc021e (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8e0adf3d-7569-4909-bab1-5fed9578ad77 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4a2aad53-fcba-2a61-e063-6394a90a6016 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:79e2620d-6554-4e03-8087-59ec2e4dd75b (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2bb63404-7d54-4482-8377-6ff02052892a (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ac08ea7d-f529-42ca-850a-a0ecce7dc830 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4238a064-1bfd-4ce3-b9d9-12c96eee8af0 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b55b6172-d986-4fd9-ba85-a8393c908949 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:879630ff-662a-40bd-b74f-a864661dea95 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c5416a9f-1dcc-4851-bbc0-6664d22fc8fa (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:640936ee-55a6-47ae-a1ad-cffae316b925 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:85a24657-583b-4776-98c9-b30285cb3058 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7835d2b0-8e5d-4d3f-a95f-9252fb65025b (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe6e39da-fb6e-46da-9c03-c765020a7c87 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6b8585a2-22e0-4a4f-a1c3-24bcdec01834 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:05a807bf-5175-43a2-a676-215bba2645a8 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:949e6bad-fcb2-42f2-b9c8-e5620ef5ccd5 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cf4f62f9-5a00-4313-b703-ec0ac6380b5e (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5f410909-a68a-4ada-963a-32018d37572f (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eff499eb-a0e4-4240-870c-83bb53434cc2 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (Cmax) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5972c6fd-08e3-4189-a894-1ba220b57e80 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4bf142a3-ad7f-4ed5-98c2-54d8509b7dbc (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:53b8d406-a4f3-46ee-9aec-d70f7d806876 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c620361a-dc2d-28a1-e053-2995a90abd14 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3c001b8d-f6c1-4316-b8c0-590b2fa7f2e5 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a337a621-bf57-4aa4-8224-4356fa2cdbc4 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33429d86-878e-4e1e-a940-70a8a56a15ea (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (Cmax) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:26065167-37c9-4e95-aa2c-3005b6805a52 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (Cmax) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eeb16efc-4413-4464-9eb8-effa1e5684aa (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (Cmax) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6e602f81-1cc3-4ae1-8bdf-85572e35cf73 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5b6f8a18-8f8a-4521-81c3-3a39c73c6646 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:812d2d57-14d6-48a9-9687-85c2d125197e (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c35408d2-a4b5-43de-8dab-f74a60fa9853 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:409e06ad-2ea9-4b47-829e-57139e22eac9 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:25431c8c-9f6e-42e7-ab84-4b062755bfe3 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8a021ffc-8b11-4ddf-81c4-87515971fdee (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f15664a4-6b5f-4e88-ad56-c827ed90a40c (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1be698df-30a0-4117-8c24-7253af94c8ad (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8466711a-3a02-4675-96db-c7cffdb89778 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d5658d8a-f8e9-454d-89a9-34884e753001 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92969ed0-8dcd-4c6d-b0c4-e8469c2f65a9 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (Cmax) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9d9f1c08-4f65-484c-943e-7e664281910f (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16754802-d5a4-0350-e063-6394a90aa967 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (Cmax) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ba299e7-0651-c23b-e063-6294a90a0245 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (Cmax) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:04f0107b-4194-4412-9ebb-3219da5a9ac9 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (Cmax) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:98f930d5-f7c2-4870-92b4-0ad37ce45797 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eff8b514-bb7f-427e-a267-7dee25fff611 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (Cmax) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe80fd21-fa8d-474e-ac0a-23f0e1eb7f3b (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8c94d403-809b-43b9-834f-3ecd330d2dd9 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e64c3b3b-d5e7-6d46-e053-2a95a90a1b64 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cae6cb47-0a2c-4c69-894b-89d389cab49f (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (Cmax) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:67aa498d-edf6-45b8-a3fd-019c3fb76960 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:24e308cc-7cec-4054-9627-66f743ed71b0 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b02ff20e-3f0e-43f4-a7b5-6ce56295d023 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e210f962-9b91-46c6-af8f-9f9a9ae84245 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7afa79de-d42e-4429-874d-449d47a59fbe (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:afcfc1eb-29b1-46e8-a013-5cbb1737a232 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (Cmax) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c49a7f23-2af0-4607-9f21-114970f8630d (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7f78d14a-acf2-4f82-9d20-dfcbd5e9ffb3 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dc3f1fd4-5578-4c5d-be7b-12e3f8f3e7df (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:38f7f201-3a3a-4922-bde7-d34187b4c81d (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8acdc142-aa38-4fcb-bd15-fbba9635a4c6 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f4d89ab-58c8-27ea-e063-6394a90a8723 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16752f60-655a-f727-e063-6394a90a96b6 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (Cmax) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a49d951-dd1b-413b-99e5-d3119267c46c (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e43e5643-b258-469d-812a-887f913cfe71 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (Cmax) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:865c2765-5072-d029-e053-2a91aa0a098e (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57dc737b-01e2-4b22-991f-d4710950dcf3 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1df1ff60-6be5-4018-a28c-0d23e5867eba (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
After oral administration, the peak plasma concentration (C max ) of olmesartan is reached after 1 to 2 hours.
Projected row 1127
- Medicine slug
- olmesartan-medoxomil
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 73
- Source count
- 73
- Agreement rate
- 1
- Recorded readings
17 L
- Numeric value
- 17
- Unit
- L
- Source records
- 73
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 73 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b57e47a5-43e0-d1c5-e053-2a95a90a2b07 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a4ceea38-8fff-4317-be04-8dc22222ec70 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1f430fc9-bd4c-4328-a4a2-501ec991029b (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:142b735a-e1cd-46e1-a523-3ef061001bf9 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e5dbca00-4e1b-4479-b829-021b11bc021e (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8e0adf3d-7569-4909-bab1-5fed9578ad77 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4a2aad53-fcba-2a61-e063-6394a90a6016 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:79e2620d-6554-4e03-8087-59ec2e4dd75b (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2bb63404-7d54-4482-8377-6ff02052892a (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ac08ea7d-f529-42ca-850a-a0ecce7dc830 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4238a064-1bfd-4ce3-b9d9-12c96eee8af0 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b55b6172-d986-4fd9-ba85-a8393c908949 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:879630ff-662a-40bd-b74f-a864661dea95 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c5416a9f-1dcc-4851-bbc0-6664d22fc8fa (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:640936ee-55a6-47ae-a1ad-cffae316b925 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:85a24657-583b-4776-98c9-b30285cb3058 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7835d2b0-8e5d-4d3f-a95f-9252fb65025b (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe6e39da-fb6e-46da-9c03-c765020a7c87 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6b8585a2-22e0-4a4f-a1c3-24bcdec01834 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:05a807bf-5175-43a2-a676-215bba2645a8 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:949e6bad-fcb2-42f2-b9c8-e5620ef5ccd5 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cf4f62f9-5a00-4313-b703-ec0ac6380b5e (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5f410909-a68a-4ada-963a-32018d37572f (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eff499eb-a0e4-4240-870c-83bb53434cc2 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5972c6fd-08e3-4189-a894-1ba220b57e80 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4bf142a3-ad7f-4ed5-98c2-54d8509b7dbc (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:53b8d406-a4f3-46ee-9aec-d70f7d806876 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c620361a-dc2d-28a1-e053-2995a90abd14 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3c001b8d-f6c1-4316-b8c0-590b2fa7f2e5 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a337a621-bf57-4aa4-8224-4356fa2cdbc4 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33429d86-878e-4e1e-a940-70a8a56a15ea (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:26065167-37c9-4e95-aa2c-3005b6805a52 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eeb16efc-4413-4464-9eb8-effa1e5684aa (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6e602f81-1cc3-4ae1-8bdf-85572e35cf73 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5b6f8a18-8f8a-4521-81c3-3a39c73c6646 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:812d2d57-14d6-48a9-9687-85c2d125197e (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c35408d2-a4b5-43de-8dab-f74a60fa9853 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:409e06ad-2ea9-4b47-829e-57139e22eac9 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:25431c8c-9f6e-42e7-ab84-4b062755bfe3 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8a021ffc-8b11-4ddf-81c4-87515971fdee (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f15664a4-6b5f-4e88-ad56-c827ed90a40c (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1be698df-30a0-4117-8c24-7253af94c8ad (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8466711a-3a02-4675-96db-c7cffdb89778 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d5658d8a-f8e9-454d-89a9-34884e753001 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92969ed0-8dcd-4c6d-b0c4-e8469c2f65a9 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9d9f1c08-4f65-484c-943e-7e664281910f (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16754802-d5a4-0350-e063-6394a90aa967 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ba299e7-0651-c23b-e063-6294a90a0245 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:04f0107b-4194-4412-9ebb-3219da5a9ac9 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:98f930d5-f7c2-4870-92b4-0ad37ce45797 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eff8b514-bb7f-427e-a267-7dee25fff611 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe80fd21-fa8d-474e-ac0a-23f0e1eb7f3b (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8c94d403-809b-43b9-834f-3ecd330d2dd9 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e64c3b3b-d5e7-6d46-e053-2a95a90a1b64 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cae6cb47-0a2c-4c69-894b-89d389cab49f (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:67aa498d-edf6-45b8-a3fd-019c3fb76960 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:24e308cc-7cec-4054-9627-66f743ed71b0 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b02ff20e-3f0e-43f4-a7b5-6ce56295d023 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e210f962-9b91-46c6-af8f-9f9a9ae84245 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7afa79de-d42e-4429-874d-449d47a59fbe (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:afcfc1eb-29b1-46e8-a013-5cbb1737a232 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c49a7f23-2af0-4607-9f21-114970f8630d (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7f78d14a-acf2-4f82-9d20-dfcbd5e9ffb3 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dc3f1fd4-5578-4c5d-be7b-12e3f8f3e7df (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:38f7f201-3a3a-4922-bde7-d34187b4c81d (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8acdc142-aa38-4fcb-bd15-fbba9635a4c6 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f4d89ab-58c8-27ea-e063-6394a90a8723 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:16752f60-655a-f727-e063-6394a90a96b6 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a49d951-dd1b-413b-99e5-d3119267c46c (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e43e5643-b258-469d-812a-887f913cfe71 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:865c2765-5072-d029-e053-2a91aa0a098e (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57dc737b-01e2-4b22-991f-d4710950dcf3 (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1df1ff60-6be5-4018-a28c-0d23e5867eba (opens source in a new tab)
Olmesartan Medoxomil label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of olmesartan is approximately 17 L.
Projected row 1128
- Medicine slug
- olopatadine
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 72
- Source count
- 5
- Agreement rate
- 1
- Recorded readings
57%
- Numeric value
- 57
- Unit
- %
- Source records
- 5
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 5 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:272e8f56-ee4e-456f-ab98-3e40f657c630 (opens source in a new tab)
Olopatadine label
Version not recorded · Effective date not recorded
The average absolute bioavailability of intranasal olopatadine is 57%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:126ff6eb-62ae-46f2-ab1e-7ac19346c36b (opens source in a new tab)
Olopatadine label
Version not recorded · Effective date not recorded
The average absolute bioavailability of intranasal olopatadine is 57%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3aa27224-7b72-38eb-0c21-b8d73525ee85 (opens source in a new tab)
Olopatadine label
Version not recorded · Effective date not recorded
The average absolute bioavailability of intranasal olopatadine is 57%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:806e8d0f-ff42-4d6e-b840-49e3bf867cb5 (opens source in a new tab)
Olopatadine label
Version not recorded · Effective date not recorded
The average absolute bioavailability of intranasal olopatadine is 57%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db024b9c-681f-4503-9fda-1eaa1add4746 (opens source in a new tab)
Olopatadine label
Version not recorded · Effective date not recorded
The average absolute bioavailability of intranasal olopatadine is 57%.
Projected row 1129
- Medicine slug
- olopatadine
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 72
- Source count
- 7
- Agreement rate
- 0.857143
- Recorded readings
8 to 12 hours
- Numeric value
- 8
- Unit
- hours
- Source records
- 6
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 6 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:272e8f56-ee4e-456f-ab98-3e40f657c630 (opens source in a new tab)
Olopatadine label
Version not recorded · Effective date not recorded
Elimination The plasma elimination half-life of olopatadine is 8 to 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:126ff6eb-62ae-46f2-ab1e-7ac19346c36b (opens source in a new tab)
Olopatadine label
Version not recorded · Effective date not recorded
Elimination The plasma elimination half-life of olopatadine is 8 to 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3aa27224-7b72-38eb-0c21-b8d73525ee85 (opens source in a new tab)
Olopatadine label
Version not recorded · Effective date not recorded
Elimination The plasma elimination half-life of olopatadine is 8 to 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:806e8d0f-ff42-4d6e-b840-49e3bf867cb5 (opens source in a new tab)
Olopatadine label
Version not recorded · Effective date not recorded
Elimination The plasma elimination half-life of olopatadine is 8 to 12 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dbcdf10c-5adb-4d48-97ce-f4b82c6bc77d (opens source in a new tab)
Olopatadine label
Version not recorded · Effective date not recorded
The elimination half-life in plasma following oral dosing was 8 to 12 hours, and elimination was predominantly through renal excretion.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db024b9c-681f-4503-9fda-1eaa1add4746 (opens source in a new tab)
Olopatadine label
Version not recorded · Effective date not recorded
Elimination The plasma elimination half-life of olopatadine is 8 to 12 hours.
3 hours
- Numeric value
- 3
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7b36e554-d68a-47e0-bf3c-f4cfdc3746b6 (opens source in a new tab)
Olopatadine label
Version not recorded · Effective date not recorded
The half-life in plasma was approximately 3 hours, and elimination was predominantly through renal excretion.
Projected row 1130
- Medicine slug
- olopatadine
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 72
- Source count
- 5
- Agreement rate
- 1
- Recorded readings
55%
- Numeric value
- 55
- Unit
- %
- Source records
- 5
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 5 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:272e8f56-ee4e-456f-ab98-3e40f657c630 (opens source in a new tab)
Olopatadine label
Version not recorded · Effective date not recorded
Distribution The protein binding of olopatadine was moderate at approximately 55% in human serum, and independent of drug concentration over the range of 0.1 to 1000 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:126ff6eb-62ae-46f2-ab1e-7ac19346c36b (opens source in a new tab)
Olopatadine label
Version not recorded · Effective date not recorded
Distribution The protein binding of olopatadine was moderate at approximately 55% in human serum, and independent of drug concentration over the range of 0.1 to 1000 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3aa27224-7b72-38eb-0c21-b8d73525ee85 (opens source in a new tab)
Olopatadine label
Version not recorded · Effective date not recorded
Distribution The protein binding of olopatadine was moderate at approximately 55% in human serum, and independent of drug concentration over the range of 0.1 to 1000 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:806e8d0f-ff42-4d6e-b840-49e3bf867cb5 (opens source in a new tab)
Olopatadine label
Version not recorded · Effective date not recorded
Distribution The protein binding of olopatadine was moderate at approximately 55% in human serum, and independent of drug concentration over the range of 0.1 to 1,000 ng/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:db024b9c-681f-4503-9fda-1eaa1add4746 (opens source in a new tab)
Olopatadine label
Version not recorded · Effective date not recorded
Distribution The protein binding of olopatadine was moderate at approximately 55% in human serum, and independent of drug concentration over the range of 0.1 to 1000 ng/mL.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=1120Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.